Le vendredi 28 octobre
14:30 – 16:30 (2 hrs)
Salle de réunion : Sheraton Hall A
Valerie Primeau*, MD, FRCPC; Andriy V. Samokhvalov, MD, PhD, FRCPC
Parrainè par le Section sur la toxicomanie

Rôles CanMEDS :

1. Expert médical
2. Collaborateur
3. Promoteur de la santé

À la conclusion de cette activité, les participants seront en mesure de : 1) Describe the different medications used to treat alcohol use disorder (AUD); 2) Apply current principles for the management of alcohol withdrawal; and 3) Identify the importance of concurrent integrated treatment and recognize the impact of the COVID-19 pandemic on prevalence and treatment of AUD.

In any given year, one in five Canadians experiences a mental health or addiction problem. People with mental illness are twice as likely to have a substance use disorder, with at least 20% of people with mental illness having a co-occurring substance use disorder. For people with schizophrenia, the number may be as high as 50%. Similarly, people with substance use disorders are up to three times more likely to have a mental illness, with more than 15% of people with substance use disorders having a co-occurring mental illness. Alcohol use disorder (AUD) is the most prevalent addiction, with a lifetime prevalence of 18.1% in Canada. With the COVID-19 pandemic, alcohol sales have markedly increased. Frequency of drinking, days of heavy drinking, and alcohol-related consequences have all increased, especially in women. Unfortunately, despite the high prevalence of AUD in clinical practice, psychiatrists are not always familiar with the available evidence-based treatments for AUD, and there is significant variability in the treatments offered to patients. Some psychiatrists are not comfortable prescribing anti-craving medications. Some may feel it is best to wait for abstinence before treating underlying mental illness. There is strong evidence that treating mental health and addictions together has the best outcome, leading to a decrease in relapse rates and health care costs. This course will review evidence-based guidelines and clinical strategies for the treatment of AUD and concurrent mental illness. Clinical vignettes will be used to help clinicians think through real-life scenarios in treating AUD.

Références :

1. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry 2018;175(1):86–90.
2. Samokhvalov AV, Probst C, Awan S, et al. Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study. BMC Psychiatry 2018;18(1):189.